Chemotherapy Patients with C. difficile Colitis Have Outcomes Similar to Immunocompetent C. difficile Patients

Journal of Gastrointestinal Surgery

Volumn 16, Issue 8, 2012, Pages 1566-1572

  Stewart, David B ^a   Yacoub, Emmanuel ^a   Zhu, Junjia ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy; Clostridium difficile; Colectomy; Colitis; Immunocompetent; Immunosuppression

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; METRONIDAZOLE; VASOCONSTRICTOR AGENT;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CHI SQUARE DISTRIBUTION; CLOSTRIDIUM DIFFICILE; COHORT ANALYSIS; COLON RESECTION; COMPARATIVE STUDY; EVALUATION; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INTENSIVE CARE; LENGTH OF STAY; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PSEUDOMEMBRANOUS COLITIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; CLOSTRIDIUM DIFFICILE; COHORT STUDIES; COLECTOMY; COMBINED MODALITY THERAPY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; INTENSIVE CARE; LENGTH OF STAY; LINEAR MODELS; MALE; METRONIDAZOLE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 84864098452     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-1930-6     Document Type: Article

References (26)

1. Bilgrami S, Feingold JM, Dorsky et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 1039-42.
2. Raza S, Baig MA, Russell H, Gourdet Y, Berger BJ. Clostridium difficile infection following chemotherapy. Recent Pat. Antiinfect Drug Discov 2010; 5: 1-9.
3. Dubberke ER, Resk KA, Srivastava A et al. Clostridium difficile-associated disease in allogenic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant 2009; 24: 192-98.
4. Hear SR, Wren B, Barnett MJ, Thomas JM, Tabaqchali S. Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains. Epidemiol Infect 1998; 100: 63-72.
5. Hornbuckle K, Chak A, Lazarus HM, et al. Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol 1998; 9: 307-11.
6. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17: 109-13.
7. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26: 1027-34.
8. Wade DS, Nava HR, Douglass HOJ. Neutropenic enterocolitis clinical diagnosis and treatment. Cancer 1992; 69: 17-23.
9. Morris-JG J, Jarvis WR, Nunez-Montiel OL, et al. Clostridium difficile: colonization and toxin production in a cohort of patients with malignant hematologic disorders. Arch Intern Med 1984; 144: 967-69.
10. Gorschluter M, Glasmacher A, Hahn C, Schakowski F, et al. Clostridium difficile Infection in Patients with Neutropenia. Clin Infect Dis 2001; 33: 786-91.
11. Arrango JI, Restrepo A, Schneider DL, et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 2006; 37: 517-21.
12. Blot E, Escande MC, Besson D et al. Outbreak of Clostridium difficile-related diarrhea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect 2003; 53: 187-92.
13. Karlstrom O, Fryklund B, Tullus K, et al. Swedish C. difficile study group. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. Clin Infect Dis 1998; 26: 141-45.
14. McDonald CL, Kilgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-41.
15. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-72.
16. Clabots CR, Johnson S., Peterson LR, Mulligan ME, et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992; 166: 561-67.
17. Colarian J. Clostridium difficile colitis following antiviral therapy in the acquired immunodeficiency syndrome. Am J Med 1988; 84: 1081.
18. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl Med 1989; 320: 204-10.
19. Gorschulter M, Glasmacher A, Hahn C, et al. Severe abdominal infections in neutropenic patients. Cancer Invest 2001; 19: 669-77.
20. Chopra T, Alangaden GJ, Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 2010; 8: 1113-19.
21. Taylor SG, Hass GM, Crumrine JL, Slaughter DP. Toxic reactions of 4-amino-pteroylglutamic acid (aminopterin) in patients with far-advanced neoplastic disease. Cancer 1950; 3: 493-03.
22. Ishibashi N, Shoji Y. Probiotics and safety. Am J Clin Nutr 2001; 73: 465 S-470 S.
23. Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am 2001; 30: 753-777, IX-X.
24. Cottrell GS, Amadesi S, Pikios S, Camerer E, Willardsen JA, et al. Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis. Gastroenterology 2007; 132: 2422-37.
25. Ausiello CM, Cerquetti M, Fedele G, Spensieri F, et al. Surface layer proteins from Clostridium difficile induce inflammatory and regulatory in human monocytes and dendritic cells. Microbes Infect 2006; 8: 2640-46.
26. Brito GAC, Sullivan GW, Ciesla WP, HT Carper, Mandell GL, Guerrant RL. Clostridium difficile toxin A alters in-vitro adherent neutrophil morphology and function. J Infect Dis 2002; 185(9): 1297-306.